OBJECTIVE: To evaluate the therapeutic effect of @entity1667 for electrical @entity159 during sleep (ESES) in @entity1 . METHOD: The clinical and EEG data of 82 @entity302 @entity1 with ESES, which included @entity302 with centro temporal spikes (BECT) variants, @entity302 with @entity25 ( @entity25 ) , @entity12924 ( @entity12924 ) collected from department of pediatrics, Peking University First Hospital were analyzed from July 2007 to September 2012. During ESES period, all @entity1 received @entity1667 treatment for three courses, which included @entity1667 intravenous infusion for three days, followed by oral @entity229 for four days every time. After three courses, @entity229 [1-2 mg/(kg * d)] were taken by all @entity1 for 6 months. The ESES phenomenon and @entity410 were observed before and after treatment. The efficacy of corticosteroid on ESES suppression, @entity410 control of three @entity302 were analyzed. RESULT: Thirty-nine cases were male and 43 cases were female. The @entity302 syndromes included 49 @entity1 diagnosed as @entity302 with centrotemporal spike (BECT) variants, 27 @entity1 diagnosed as @entity302 with @entity25 ( @entity25 ), and 6 @entity1 diagnosed as @entity12924 . Age of onset ranged from 1 year and 4 months to 11 years. The age of ESES newly monitored was from 2 years to 10 years and 8 months. The total effective rate of corticosteroid was 83% (68/82) for ESES, BECT variants was 82% (40/49), @entity25 was 81% (22/27), @entity12924 was 100% (6/6). There was no statistically significant difference in effective rates between the front two (     = 0.09, P > 0.05). The @entity410 were improved in the first month after @entity1667 treatment in 3 @entity302 syndromes. The recurrence rate of BECT variants was 47% (23/49) , @entity25 was 59% (16/27) , @entity12924 was 50% (3/6) after 1 year follow up. There was no association between disease parameters, including age at @entity410 onset, duration of ESES and the treatment effect of ESES examined by Kruskal-Wallis method (     = 3.585, 0.932, P > 0.05). CONCLUSION: @entity1667 was effective for improving ESES and @entity410 in 3 @entity302 syndromes combined with ESES. There was no significant correlation between age at @entity410 onset, duration of ESES and treatment effect of ESES.

[Efficacy of @entity1667 therapy for electrical XXXX during sleep in @entity1 ].

@entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone', 'Methylprednisolone'] @entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures'] @entity12924 :: ('MESH:D018887', 'Disease') :: ['Landau-Kleffner syndrome', 'LKS'] @entity25 :: ('MESH:D012893', 'Disease') :: ['continuous spikes and waves during slow sleep', 'CSWS'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity302 :: ('MESH:D004827', 'Disease') :: ['benign childhood epilepsy', 'epilepsy', 'epilepsy syndrome'] @entity159 :: ('MESH:D013226', 'Disease') :: ['status epilepticus']
@entity159 :: (MESH:D013226,Disease) :: ['status epilepticus']
